TransEnterix Announces Closing of $31.25 Million Registered Direct Offering of Common Stock
14 Enero 2021 - 1:23PM
Business Wire
- Proceeds from offering, in combination with recent financing
activity, extends cash runway into the fourth quarter of 2022
TransEnterix, Inc. (NYSE American:TRXC), a medical device
company that is digitizing the interface between the surgeon and
the patient to improve minimally invasive surgery, today announced
the closing of its previously announced registered direct offering
of 25,000,000 shares of its common stock. The offering was priced
at a purchase price per share of $1.25, for gross proceeds of
approximately $31.25 million.
TransEnterix intends to use the net proceeds from the offering
for general corporate purposes, including working capital.
H.C. Wainwright & Co. acted as the exclusive placement agent
for the offering.
A shelf registration statement on Form S-3 (File No. 333-236200)
relating to the registered direct offering of the shares of common
stock described above was filed with the Securities and Exchange
Commission (“SEC”) and was declared effective on February 10, 2020.
The offering of the shares of common stock was made only by means
of a prospectus supplement and accompanying prospectus that forms a
part of the registration statement. Electronic copies of the final
prospectus supplement and the accompanying prospectus have been
filed with the SEC and may be obtained from H.C. Wainwright &
Co., LLC, 430 Park Avenue, 3rd Floor, New York, NY 10022, by
calling (646) 975-6996 or by emailing placements@hcwco.com or at
the SEC’s website at http://www.sec.gov. This press release shall
not constitute an offer to sell, or the solicitation of an offer to
buy, nor shall there be any sale of these securities in any state
or jurisdiction in which such an offer, solicitation or sale would
be unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
Balance Sheet Update
The Company believes that cash on hand, proceeds from the ATM
Offering and the Series C and Series D Warrant exercises, as well
as the proceeds from this offering will be sufficient to fund
operations into the fourth quarter of 2022.
About TransEnterix
At TransEnterix, Inc., we are digitizing the interface between
the surgeon and the patient to improve minimally invasive surgery
(MIS) through a new category of care called Digital Laparoscopy.
Digitizing the interface enables the use of advanced capabilities
like augmented intelligence, connectivity and robotics in
laparoscopy, and allows us to address the current clinical,
cognitive and economic shortcomings in surgery. The system features
the first machine vision system for use in robotic surgery which is
powered by the new Intelligent Surgical Unit™ (ISU™) that enables
augmented intelligence in surgery. The Senhance® Surgical System
brings the benefits of Digital Laparoscopy to patients around the
world while staying true to the principles of value-based
healthcare. Learn more about Digital Laparoscopy with the Senhance
Surgical System here: https://Senhance.com/. Now available for sale
in the US, the EU, Japan, Russia, and select other countries. For a
complete list of indications for use, please visit:
https://www.transenterix.com/indications-for-use/.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including statements about the intended use of proceeds from
the registered direct offering and our expected cash reach. These
statements involve significant risks and uncertainties, including
those discussed in the prospectus supplement related to the
offering and in our annual report on Form 10-K for the fiscal year
ended December 31, 2019 and our other filings with the SEC. Because
these statements reflect our current expectations concerning future
events, our actual results could differ materially from those
anticipated in these forward-looking statements as a result of many
factors. We are providing this information as of January 14, 2021.
We undertake no duty to update any forward-looking statements to
reflect the occurrence of events or circumstances after the date of
such statements or of anticipated or unanticipated events that
alter any assumptions underlying such statements, except as
required by law..
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210114005932/en/
For TransEnterix, Inc. Investor Contact: Mark Klausner, +1
443-213-0501 invest@transenterix.com
Or
Media Contact: Terri Clevenger, +1 203-682-8297
terri.clevenger@icrinc.com
TransEnterix (AMEX:TRXC)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
TransEnterix (AMEX:TRXC)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024